eligibility_summary
Adults ≥18, adequate cardiac/pulmonary function and labs. RA: dx, refractory to b/tsDMARDs, ≥6 SJC/TJC. PV: active, Dsg1/3+, refractory. GPA/MPA: dx, ANCA+, refractory. SLE: criteria, SLEDAI≥8, dsDNA+, failed ≥2 therapies, stable SOC, OCS<20 mg. Key exclusions: recent cyclophosphamide/B-cell tx, IVIG/plasmapheresis, prior cell therapy, transplants, malignancy (esp B-cell), cardiac/pulmonary disease, recent infection/vaccines, HIV, pregnancy, tobacco use or ≥5 pack-yrs, low IgG, uncontrolled illness.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1, open-label, single-center trial testing a combination of: 1) AB-101 (AlloNK) — an off‑the‑shelf allogeneic, expanded NK cell therapy designed to kill antibody‑opsonized targets via FcγRIIIa (CD16)–mediated ADCC, 2) Rituximab — a chimeric anti‑CD20 monoclonal antibody that depletes B cells via ADCC, complement (CDC), and apoptosis, with 3) Fludarabine (purine analog) and 4) Cyclophosphamide (alkylator) as lymphodepletion to enhance NK cell persistence/expansion. Targets/pathways: CD20+ B lymphocytes and downstream autoantibody pathways, NK cell cytotoxic/ADCC pathways, complement activation. Diseases: RA, PV, GPA/MPA, SLE—aiming to reduce pathogenic B cells producing anti‑Dsg1/3, ANCA, anti‑dsDNA and other autoantibodies.